Publications by authors named "S Champiat"
Article Synopsis
- Tarlatamab, an immunotherapy targeting delta-like ligand 3, shows promising anticancer effects in small cell lung cancer (SCLC) based on the DeLLphi-300 and DeLLphi-301 trials, with manageable safety profiles.
- In the extended follow-up of DeLLphi-300, the overall response rate was 25%, with a median duration of response of 11.2 months and a median overall survival of 17.5 months across 152 patients.
- Among those receiving a specific dose regimen (10 mg every two weeks), 35.3% experienced a response, and notable intracranial tumor shrinkage was found in patients with existing brain lesions, highlighting tarlatam
Article Synopsis
- Patients with advanced tumors in phase I trials often have strong treatment hopes but limited options; local ablative stereotactic radiation therapy (SRT) can help manage disease progression when oligoprogressive resistance occurs.* -
- A study analyzed 42 patients receiving SRT for oligoprogressive lesions, finding that SRT significantly extended progression-free survival (7.1 months) and time to the next treatment (12.8 months), with no severe toxicities reported.* -
- The findings suggest that tumor characteristics, like aggressiveness and clonal diversity, can help distinguish between patients needing different management strategies after SRT, potentially enhancing treatment outcomes.*
Article Synopsis
- Antibody-drug conjugates (ADCs) are a promising cancer treatment that combines targeted monoclonal antibodies with potent drugs, relying on the expression levels of target proteins in cancer cells for effectiveness.
- This review analyzes clinical trial results from January 2019 to May 2023, highlighting approved ADCs that show efficacy even in tumors with low levels of target protein expression.
- It emphasizes the challenges in accurately assessing target protein levels due to inconsistent evaluation methods and the complexity of ADC behavior in the body, advocating for standardized approaches to improve future ADC therapies.
Purpose: With liquid biopsy's widespread adoption in oncology, an increased number of clonal hematopoiesis-associated mutations (CHm) have been identified in patients with solid tumors. However, its impact on patient outcomes remains unclear. This study aimed to analyze and describe CHm in a cohort of phase I patients.
View Article and Find Full Text PDFT-cell engagers (TCE) are cancer immunotherapies that have recently demonstrated meaningful benefit for patients with hematological malignancies and solid tumors. The anticipated widespread use of T cell engagers poses implementation challenges and highlights the need for guidance to anticipate, mitigate, and manage adverse events. By mobilizing T-cells directly at the contact of tumor cells, TCE mount an obligatory and immediate anti-tumor immune response that could result in diverse reactions and adverse events.
View Article and Find Full Text PDF